Immatics

US · IMTX #3173 by market cap Listed 2018

7.22 -0.24 -3.15%

Live - 5344 symbols - heartbeat 523s ago · 2026-10-08 10:00

Pre-market 7.47 +0.27%

After-hours 7.88 +5.77%

Overnight 7.46 +0.13%

Market cap: 1.08B
P/E (TTM): -4.05
P/B: 2.41
EPS: -1.80
Div yield: 0.00%
52W pos: 0%

Reader sentiment Are you bullish or bearish on IMTX?

Anonymous reader poll. Unscientific, not investment advice.

About Immatics

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

Founded: 2020
CEO: Dr. Harpreet Singh, PhD
Employees: 711
Headquarters: Tuebingen, Baden Wuerttemberg, Germany
Fiscal year end: 12-31
Website: immatics.com

Company profile

Exchange: US
Symbol: IMTX
Market-cap rank: #3173
Listing date: 2018-10-05
Market cap: 1.08B
Float cap: 599.32M
Shares out: 149.64M
Float shares: 83.07M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 10:00:05 · For reference only, not investment advice and not tailored to your situation.